All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @pagesix on TikTok · 45s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @pagesix's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I did not do like an ozimpic.
  2. 0:04I tried it.
  3. 0:05We tried it once when no one knew what it was.
  4. 0:09And it made me really sick.
  5. 0:11I called her up one day and I go, I can't work anymore.
  6. 0:14I can't.
  7. 0:14I'm so sick.
  8. 0:15I can't like nauseous.
  9. 0:18And so she goes, OK, OK, let's try something else.
  10. 0:20And so the more we, you know, kind of dialed around
  11. 0:24and looked at different options, I realized
  12. 0:26that a peptide injection was really great for me.
  13. 0:31And then I follow it up with supplements like she'll call me.
  14. 0:35Dr. A will say, you need like the fish oil.
  15. 0:39I'll go three.
  16. 0:40Yeah.
  17. 0:41And all that stuff to make sure that I have what
  18. 0:43I need to be taking.

Kris Jenner and Ozempic: what celebrity use actually tells us

Page Six

TikTok creator

975.2K viewsWatch on TikTok

Quick answer

Kris Jenner describes a single trial of semaglutide that produced significant nausea and functional impairment, a well-documented side effect affecting up to 44% of users in clinical trials, followed by a switch to an unspecified peptide injection under physician guidance. The clinical takeaway is that GLP-1 intolerance exists on a spectrum and should prompt dose adjustment or a switch to an alternative agent, not self-directed experimentation with unnamed peptide compounds. Supplement co-administration, including omega-3s, is sometimes clinically appropriate alongside GLP-1 therapy due to reduced caloric intake, but is not a standardized protocol.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Kris Jenner and Ozempic: what celebrity use actually tells us, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Kris Jenner and Ozempic: what celebrity use actually tells us" from Page Six. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Kris Jenner describes a single trial of semaglutide that produced significant nausea and functional impairment, a well-documented side effect affecting up to 44% of users in clinical trials, followed by a switch to an unspecified peptide injection under physician guidance.

The reason this review is not generic is the source wording and the canonical claim label "glp1 kris jenner finally confirms she tried ozempic after specula." In this clip, the useful excerpt is: "I did not do like an ozimpic." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

GI intolerance to one GLP-1 agent does not disqualify a patient from the drug class.
People who land here are usually trying to understand whether the Compounded Semaglutide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Kris Jenner describes a single trial of semaglutide that produced significant nausea and functional impairment, a well-documented side effect affecting up to 44% of users in clinical trials, followed by a switch to an unspecified peptide injection under physician guidance.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Kris Jenner describes a single trial of semaglutide that produced significant nausea and functional impairment, a well-documented side effect affecting up to 44% of users in clinical trials, followed by a switch to an unspecified peptide injection under physician guidance. The clinical takeaway is that GLP-1 intolerance exists on a spectrum and should prompt dose adjustment or a switch to an alternative agent, not self-directed experimentation with unnamed peptide compounds. Supplement co-administration, including omega-3s, is sometimes clinically appropriate alongside GLP-1 therapy due to reduced caloric intake, but is not a standardized protocol.
  • Up to 44% of semaglutide users experience nausea, and GI side effects were the top reason for discontinuation in the STEP 1 trial (Wilding et al., 2021, NEJM).
  • GI intolerance to one GLP-1 agent does not disqualify a patient from the drug class. Tirzepatide showed a distinct tolerability profile in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM).

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Up to 44% of semaglutide users experience nausea, and GI side effects were the top reason for discontinuation in the STEP 1 trial (Wilding et al., 2021, NEJM).
  • GI intolerance to one GLP-1 agent does not disqualify a patient from the drug class. Tirzepatide showed a distinct tolerability profile in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM).
  • 'Peptide injection' is not a medical term. Without knowing the specific compound, no one watching this video can evaluate its safety, efficacy, or legal status.
  • Omega-3 supplementation has cardiovascular evidence (REDUCE-IT trial, Bhatt et al., 2019, NEJM) but is not established as a required co-treatment with GLP-1 or peptide therapy.
  • Compounded peptide products are not FDA-approved drugs and are not equivalent to brand-name GLP-1 medications. Formulation, dosing accuracy, and sterility vary significantly.
  • Patients experiencing significant nausea on GLP-1 therapy should discuss slower dose titration, antiemetic strategies, or alternative agents with their prescribing clinician before stopping.
  • Physician involvement in Jenner's regimen is the most responsible element of this disclosure, but celebrity supervision is not a template. Your clinical needs require your own evaluation.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @pagesix actually say?

Kris Jenner, speaking on the "She MD" podcast, confirmed she tried semaglutide (Ozempic) once, said it made her "really sick" and "nauseous," and then switched to what she calls "a peptide injection" on the advice of a doctor she refers to as "Dr. A." She also said she stacks the injection with supplements including fish oil.

To be precise about what she actually claimed: she didn't call it a treatment for any condition. She didn't name a dose. She framed it as personal experimentation done before Ozempic was a household name, supervised by a physician. That framing is actually more responsible than most celebrity weight-loss disclosures. Still, there's a lot to unpack, particularly the vague "peptide injection" claim and the supplement stacking.

Does the science back this up?

Nausea as a side effect of semaglutide is extremely well-documented, so her experience checks out. The supplement claim is shakier.

GLP-1 receptor agonists like semaglutide cause nausea in roughly 20-44% of users, particularly at the start of treatment or during dose escalation. This is consistently reported across pivotal trials including the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), where gastrointestinal side effects were the most common reason for discontinuation. Jenner saying she felt too sick to work after one trial is consistent with what we know about first-dose GI sensitivity in some patients.

The fish oil recommendation is trickier. Omega-3 supplementation has some evidence for cardiovascular benefit (Bhatt et al., 2019, NEJM, the REDUCE-IT trial), but the idea that it's a standard complement to peptide therapy isn't established in clinical literature. It's not harmful. It's just not proven as a necessary "stack."

What did they get wrong (or right)?

The biggest problem here is the phrase "a peptide injection." This is doing a lot of heavy lifting with no specificity, and that vagueness is a real issue for anyone watching this video hoping to replicate her results.

"Peptide" is a broad biochemical category. It could refer to anything from tirzepatide to BPC-157 to CJC-1295 to dozens of other compounds, some of which are FDA-approved, many of which are not, and some of which have very little human safety data. When a celebrity says a peptide injection "was really great for me" to nearly a million viewers, the lack of specificity isn't humility, it's a gap that can push people toward unregulated products.

What she got right: she had a physician involved, she described a real and documented side effect accurately, and she didn't claim her approach cures anything or that everyone should do what she did. For a celebrity disclosure, that's better than average.

What should you actually know?

GLP-1 intolerance is real and affects a meaningful percentage of patients. It does not mean weight management pharmacotherapy is off the table.

If semaglutide causes intolerable nausea, there are legitimate clinical alternatives. Tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 agonist, has a different tolerability profile for some patients (Jastreboff et al., 2022, NEJM). Dose titration strategies can also reduce GI side effects significantly, and some patients do better with liraglutide. The point is: a bad reaction to one GLP-1 agent should prompt a clinical conversation, not a pivot to unspecified "peptide injections" sourced from wherever.

The supplement angle also deserves scrutiny. Omega-3s, vitamin D, and similar supplements are often added alongside GLP-1 therapy because patients on these medications can lose muscle mass and micronutrient intake may drop alongside caloric intake. That's a legitimate clinical concern (Wilding et al., 2021). But the supplements themselves are not the therapy, and their benefit depends heavily on baseline deficiency and individual health status.

Bottom line: how worried should you be about this video?

Moderately. Jenner's personal account of semaglutide nausea is credible and accurate. The physician-supervised framing is responsible. But "a peptide injection" with no further detail, reaching nearly a million viewers, is the kind of vague celebrity language that sends people down unregulated rabbit holes. If you're watching this and thinking about trying "peptides" for weight management, that conversation needs to happen with a licensed clinician who knows your full history, not a podcast clip.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Page Six · TikTok creator

975.2K views on this video

Kris Jenner finally confirms she tried Ozempic after speculation. 🎥: "She MD" podcast

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about up to 44% of semaglutide users experience nausea,?

Up to 44% of semaglutide users experience nausea, and GI side effects were the top reason for discontinuation in the STEP 1 trial (Wilding et al., 2021, NEJM).

What does the video say about gi intolerance to one glp-1 agent does not disqualify a?

GI intolerance to one GLP-1 agent does not disqualify a patient from the drug class. Tirzepatide showed a distinct tolerability profile in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM).

What does the video say about 'peptide injection'?

'Peptide injection' is not a medical term. Without knowing the specific compound, no one watching this video can evaluate its safety, efficacy, or legal status.

What does the video say about omega-3 supplementation has cardiovascular evidence (reduce-it trial, bhatt et al.,?

Omega-3 supplementation has cardiovascular evidence (REDUCE-IT trial, Bhatt et al., 2019, NEJM) but is not established as a required co-treatment with GLP-1 or peptide therapy.

What does the video say about compounded peptide products?

Compounded peptide products are not FDA-approved drugs and are not equivalent to brand-name GLP-1 medications. Formulation, dosing accuracy, and sterility vary significantly.

What does the video say about patients experiencing significant nausea on glp-1 therapy should discuss slower?

Patients experiencing significant nausea on GLP-1 therapy should discuss slower dose titration, antiemetic strategies, or alternative agents with their prescribing clinician before stopping.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Page Six, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.